SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008

DUBLIN, Calif., Sept. 8 SuperGen, Inc.(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapiddevelopment and commercialization of therapies for solid tumors andhematological malignancies, today announced that Michael Molkentin, ChiefFinancial Officer, and Michael V. McCullar, Ph.D., Vice President of DrugDiscovery Operations, are scheduled to co-present at the Merriman 5th AnnualInvestor Summit on Monday, September 15, 2008 at the Mark Hopkins Hotel in SanFrancisco.

SuperGen's presentation at the Merriman Investor Summit is scheduled tobegin at 8:30 a.m. PDT (11:30 a.m. EDT). A live webcast of the presentationwill be available on the investor relations section of the Company's Web siteat www.supergen.com. A webcast replay of the presentation will be availableshortly following the live event.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical companydedicated to the discovery and development of novel cancer therapies. SuperGenis developing a number of therapeutic anticancer products focused on kinaseand cell signaling inhibitors and DNA methyltransferase inhibitors. For moreinformation about SuperGen, please visit http://www.supergen.com .Contacts: SuperGen, Inc. Timothy L. Enns SVP, Corporate Communications & Business Development Tel: (925) 560-0100 Email: [email protected] Mary M. Vegh Manager, Investor Relations Tel: (925) 560-2845 E-mail: [email protected] Dorland Global Public Relations Michael Beckerich (Media) Tel: (212) 677-7632 [email protected]

SOURCE SuperGen, Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...